The finder
Pick what you want to change. See who actually measured it.
Every other tool like this gives you a compound and a match score. Those scores are not measured. Ours does not exist. What you get instead is what was actually measured and where: trials in people first with the participant count, then the animal and cell work kept separate, then what people using it report, and the trials that found nothing, counted rather than dropped.
82 of the 444 compounds here have never been through a trial in people. That is worth knowing and it is not a verdict: a molecule nobody can patent has no sponsor to pay for a trial, so a thin human record is usually a fact about money rather than about the compound. Where that is the case, this says so and shows you what does exist.
What are you trying to change?
Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive, so you can see where the evidence is before you choose.
Or start from the compounds
Somebody handed you a stack. What is actually known about it?
Add what you are looking at and you get every outcome those compounds have been measured for in people, and then the longer list of the ones they have not.
Feeling less hungry
Does it actually make you less hungry?
Separate from weight loss on purpose. Appetite is what people feel and report; weight is what the scale shows. A trial can move one without the other.
579 people · 28 human studies · 23 compounds
- 204 people1 study
16 weeks in 204 obese subjects without insulin: placebo-corrected weight loss of 3.7% (3.6 kg), showing the amylin pathway's appetite effect that later informed cagrilintide.
Journal of Clinical Endocrinology and Metabolism, 2007 · 204 people
- 187 people2 studies
187 patients with cancer cachexia and GDF15 of at least 1,500 pg/mL (40 percent non-small-cell lung, 32 percent pancreatic, 29 percent colorectal) randomised 1:1:1:1 to ponsegromab 100, 200 or 400 mg or placebo every 4 weeks for three doses. Median weight gain versus placebo at 12 weeks: 1.22 kg (95 percent credible...
New England Journal of Medicine, 2024 · 187 people
Most GDF15 in maternal plasma is fetal or placental in origin, shown by mass spectrometry of a naturally labelled variant. Carriers of variants giving low pre-pregnancy GDF15 had higher risk of hyperemesis gravidarum; women with beta-thalassaemia, who have chronically high GDF15, reported very little nausea. In mice,...
Nature, 2024 · no headcount in the line
- 54 people1 study1 found nothing
found nothing54 adults with obesity in Denmark, 63 percent women, mean bodyweight 101.3 kg and BMI 35.2, randomised 1:1:1 to dapiglutide 4 mg, 6 mg or placebo weekly for 12 weeks with no concurrent lifestyle intervention. Primary endpoint percentage bodyweight change. The 6 mg dose produced a mean change of minus 2.1 percent...
EClinicalMedicine, 2026 · 54 people
- 40 people1 study
40 healthy Chinese volunteers, single 2.5 mg dose and weekly titration to 5, 10 and 15 mg. Maximum concentration and area under the curve were linearly proportional to dose across 2.5 to 15 mg, supporting weekly dosing. Body weight change from baseline was minus 3.24, minus 6.26, minus 7.09 and minus 8.30 percent at...
Diabetes, Obesity and Metabolism, 2025 · 40 people
- 27 people2 studies
Double-blind randomized placebo-controlled trial in 18 male volunteers given 1 or 5 micrograms per kilogram intravenously. Both doses strongly stimulated GH release and were well tolerated, with an elimination half-life of 9 to 13 minutes for acylated ghrelin; hunger tended to rise dose-dependently but not...
European Journal of Endocrinology, 2004 · 18 people
Intravenous ghrelin raised buffet energy intake by about 28% in nine healthy volunteers; first circulating hormone shown to stimulate food intake in man.
Journal of Clinical Endocrinology and Metabolism, 2001 · 9 people
- 23 people1 study1 found nothing
found nothing23 women randomised double-blind to 250 mg of a 10 percent Coleus forskohlii extract twice daily (n equals 7) or placebo (n equals 12) for 12 weeks. No significant differences in fat mass, fat-free mass or body fat percentage. Non-significant trends toward mitigating gains in body mass (p equals 0.10) and scanned mass...
Journal of the International Society of Sports Nutrition, 2005 · 23 people
- 13 people3 studies1 found nothing
found nothing13 healthy volunteers, randomised double-blind placebo-controlled crossover. Buffet energy intake fell 19.3% and 12-hour intake 11.3%, with ghrelin suppressed. Notably it caused no nausea and did not change how food tasted, which separates it from some later drugs in the class.
Journal of Clinical Endocrinology and Metabolism, 2003 · 13 people
Self-administered three times daily before meals for four weeks. Bodyweight fell 2.3 kg against 0.5 kg on control (p = 0.0106), roughly 0.45 kg a week, with energy intake at the study meal down 25% at the start and 35% by the end.
Diabetes, 2005 · no headcount in the line
The trial that separates the appetite claim from the energy expenditure claim by running oxyntomodulin against its two component signals and against the combination. Read this before believing the raises-your-metabolism half of the story.
Journal of Clinical Endocrinology and Metabolism, 2015 · no headcount in the line
- 10 people1 study
Ten men with erectile dysfunction of no known organic cause, double-blind placebo-controlled crossover with real-time RigiScan monitoring over six hours. Clinically apparent erections developed in 8 of 10 men on melanotan II. Mean duration of tip rigidity above 80% was 38.0 minutes on melanotan II against 3.0 minutes...
Journal of Urology, 1998 · 10 people
- 7 people1 study
A GHRP-2 infusion increased ad libitum intake by about 36% in seven lean men alongside a strong GH rise, so its appetite effect is reduced rather than absent.
Journal of Clinical Endocrinology and Metabolism, 2005 · 7 people
- 7 people1 study
A GHRP-2 infusion increased ad libitum food intake by about 36 percent in seven lean men alongside a strong growth hormone rise. This is the side effect that most often ends a blend course, and the one you cannot remove without also removing the sermorelin.
Journal of Clinical Endocrinology and Metabolism, 2005 · 7 people
- 3 people1 study
Phase 1 over 28 days and phase 2 over 12 weeks, both randomised, double-blind and placebo-controlled. Phase 1 produced dose-dependent weight loss with statistically significant reductions against placebo at all doses, plus reduced appetite and delayed gastric emptying. Phase 2 produced significantly greater mean...
Obesity, 2026 · 3 people
- 3 people1 study
Three children with congenital leptin deficiency treated with daily subcutaneous recombinant human leptin for up to 4 years: sustained reductions in appetite, fat mass, hyperinsulinaemia and hyperlipidaemia, rapid rise in thyroid hormones, appropriately timed puberty, and reversal of reduced CD4 T cell numbers and...
Journal of Clinical Investigation, 2002 · 3 people
- 1 people1 study1 found nothing
found nothingA fully human antibody activating the leptin receptor with or without leptin. In obese leptin knockout mice it normalised body weight, food intake, blood glucose and insulin sensitivity. In a randomised double-blind placebo-controlled two-part phase 1 it was well tolerated. Verbatim: treatment of individuals with...
Science Translational Medicine, 2023 · 1 people
- no headcount stated2 studies1 found nothing
12 overweight or obese volunteers, randomised double-blind placebo-controlled crossover. Energy intake at a test meal during combined PYY3-36 and oxyntomodulin infusion was 42.7 percent below saline and significantly below either hormone alone. Non-US government funded.
Diabetes, 2010 · no headcount in the line
found nothingSingle-blind randomised placebo-controlled crossover in obese volunteers: a 10.5-hour ambulatory subcutaneous infusion of GLP-1, oxyntomodulin and PYY at doses matching post-gastric-bypass levels (PYY 0.4 pmol/kg/min) cut food intake by a mean 32 percent with no change in resting energy expenditure. Non-US government...
Journal of Clinical Endocrinology and Metabolism, 2017 · no headcount in the line
- no headcount stated1 study
At about one year, 8 of 10 (80%) POMC-deficiency and 5 of 11 (45%) LEPR-deficiency participants lost at least 10% of body weight, with hunger scores down 27% and 44%; hyperpigmentation and injection-site reactions were near-universal.
The Lancet Diabetes & Endocrinology, 2020 · no headcount in the line
- no headcount stated1 study
Randomized double-blind placebo-controlled crossover in healthy obese subjects with a mean BMI of 39. Five days of native GLP-1 given before meals cut mean food intake per meal 15% and produced 0.55 kg of weight loss, with slowed gastric emptying as the probable mechanism. The native hormone does what its analogues...
British Journal of Nutrition, 2004 · no headcount in the line
- no headcount stated1 study
Phase 2 sub-study: weight loss was driven mainly by reduced appetite and energy intake.
Obesity, 2012 · no headcount in the line
- no headcount stated1 study
Reports reduced hunger in adults from a gut-restricted bitter taste receptor agonist, alongside weight loss in diet-induced obese mice when combined with a DPP-4 inhibitor. Note the split: the human result is on hunger, and the weight loss result is in mice and required a second drug.
Molecular Metabolism, 2026 · no headcount in the line
- no headcount stated1 study
Phase 1 dose-escalation studies in healthy American and Chinese adults. Half-life was approximately seven days in both populations and exposure was comparable between them, with geometric mean ratios for area under the curve and maximum concentration close to 1, so no ethnic pharmacokinetic difference was detected....
Diabetes, Obesity and Metabolism, 2025 · no headcount in the line
- no headcount stated1 study
GHRP-2 increased food intake in healthy men in the way ghrelin does. The appetite effect is a direct pharmacological property of this half of the blend, and it is the reason the choice of GHRP changes the experience of the product.
Journal of Clinical Endocrinology and Metabolism, 2005 · no headcount in the line
- no headcount stated1 study
GHRP-2 increased food intake in healthy men. This is the profile ipamorelin was selected to avoid, and it returns to the vial the moment GHRP-2 is added alongside it.
Journal of Clinical Endocrinology and Metabolism, 2005 · no headcount in the line
- no headcount stated1 study
GHRP-2 increased food intake in healthy men in the way ghrelin does. Both ghrelin-receptor components of this blend drive appetite, and their effects at that receptor add.
Journal of Clinical Endocrinology and Metabolism, 2005 · no headcount in the line
- no headcount stated1 study1 found nothing
found nothingPhase 2a energy balance study; 12 cotadutide and 7 placebo completers over 42 days. Weight change minus 4.0 percent against minus 1.4 percent (P equals 0.011); energy intake fell 41.3 percent against placebo; energy expenditure by doubly labelled water did not differ (1.0 percent, P equals 0.784). Weight loss was...
Diabetes, Obesity and Metabolism, 2024 · no headcount in the line
- no headcount stated0 studies
A cautionary species difference: four days of LR3 IGF-I infusion in pigs decreased daily gain, food intake, plasma GH, IGFBP-3 and endogenous IGF-I.
Journal of Endocrinology, 1997 · no headcount in the line
How this is counted
Human studies only. Animal and test-tube work never enters this ranking, because the question you asked was about a person.
A compound is listed for an outcome only when a citation on its own page states that outcome and reports a result for it. Naming it is not enough: a paper that measures testosterone and reports a result about something else does not count as testosterone evidence, which is a mistake this tool made on its first run and no longer makes.
People counts are read out of the study lines themselves and are deliberate undercounts. Where a line states no number, the study still counts as a study and adds nothing to the headcount. Counts are never added across compounds, because the same person can appear in more than one trial.
Ranking is by people measured. That is a fact about the evidence, not a judgement about the compound, and it is the only ordering this site will defend. A compound at the top of a list is the most studied, which is not the same as the best.
Nothing here is advice, and nothing here is a recommendation to take anything.